Press releases

Press release
Conversion of all class A shares in Medivir to class B shares – prospectus published

Stockholm, Sweden - Medivir AB (”Medivir” or the ”Company”) (Nasdaq Stockholm: MVIR) today announces that the prospectus, which has been prepared...

Read more
Press release
The Nomination Committee´s proposal for new Board of Directors to the Annual General Meeting 2018

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces the Nomination Committee’s proposal for a new Board of Directors to...

Read more
Press release
Medivir Announces Departure of Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that John Öhd, Chief Medical Officer at Medivir, has decided to...

Read more
Press release
New preclinical data on MIV-818 accepted for presentation at EASL’s HCC Summit in March

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new preclinical data for MIV-818 will be presented at the...

Read more
Press release
Number of shares and votes in Medivir

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed...

Read more
Press release
MEDIVIR AB – YEAR END REPORT JANUARY – DECEMBER 2017

STRONG DEVELOPMENT ACROSS THE PORTFOLIO October - December Significant events during the quarter Medivir received FDA Fast Track Designation for MIV-711...

Read more
Press release
Medivir has completed a directed share issue of approximately 155 MSEK

Stockholm, Sweden - Medivir AB (“Medivir” or the “Company”) (Nasdaq Stockholm: MVIR) today announces that the board of directors of Medivir...

Read more
Press release
Medivir intends to make a directed share issue

Stockholm, Sweden - Medivir AB (“Medivir” or the “Company”) (Nasdaq Stockholm: MVIR) today announces its intention to execute a directed issue...

Read more
Press release
Resolutions at the Extraordinary General Meeting in Medivir on 26 January 2018

The Extraordinary General Meeting in Medivir Aktiebolag (publ) (“Medivir”) on 26 January 2018 resolved, among other things, on the following; The...

Read more
Press release
Successful completion of pre-clinical safety studies with MIV-818, enabling start of phase I clinical studies in 2018

MIV-818 is Medivir’s proprietary liver-targeted nucleotide prodrug for the treatment of hepatocellular carcinoma (HCC) and other forms of liver cancer. It...

Read more
Press release
Notice of Extraordinary General Meeting of Medivir AB (publ)

The shareholders in Medivir AB are hereby summoned to an Extraordinary General Meeting on Friday 26 January 2018 at 3 pm...

Read more
Press release
Medivir’s series A shares to be converted into series B shares

Stockholm, Sweden — Medivir AB (publ) (“Medivir” or the “Company”) (Nasdaq Stockholm: MVIR) today announces that the holders of series A...

Read more